[go: up one dir, main page]

AR040764A1 - Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina - Google Patents

Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina

Info

Publication number
AR040764A1
AR040764A1 AR20030102775A ARP030102775A AR040764A1 AR 040764 A1 AR040764 A1 AR 040764A1 AR 20030102775 A AR20030102775 A AR 20030102775A AR P030102775 A ARP030102775 A AR P030102775A AR 040764 A1 AR040764 A1 AR 040764A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
pseudoefedrine
methylfedrine
epinastine
acceptable salts
Prior art date
Application number
AR20030102775A
Other languages
English (en)
Inventor
Tetsuo Hayashi
Kasuki Matsumoto
Norimitsu Umehara
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR040764A1 publication Critical patent/AR040764A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas orales que comprenden como compuestos farmacéuticamente activos una combinación de una cantidad antihistamínica efectiva de espinastina o una de sus sales farmacéuticamente aceptables y una cantidad descongestionante efectiva de pseudoefedrina o una de sus sales farmacéuticamente aceptables y metilefedrina (metilefrina) en una cantidad descongestionante efectiva o una de sus sales farmacéuticamente aceptables, La formulación comprende además vehículos o excipientes farmacéuticamente aceptables. Con la condición de que la composición no comprende Belladona.
AR20030102775A 2002-08-02 2003-08-01 Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina AR040764A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02017409 2002-08-02

Publications (1)

Publication Number Publication Date
AR040764A1 true AR040764A1 (es) 2005-04-20

Family

ID=31502688

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102775A AR040764A1 (es) 2002-08-02 2003-08-01 Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina

Country Status (11)

Country Link
US (1) US20050084527A1 (es)
EP (1) EP1531802A1 (es)
JP (1) JP2006501211A (es)
AR (1) AR040764A1 (es)
AU (1) AU2003250073A1 (es)
BR (1) BR0313175A (es)
CA (1) CA2494065A1 (es)
MX (1) MXPA05000071A (es)
PE (1) PE20040748A1 (es)
UY (1) UY27920A1 (es)
WO (1) WO2004014353A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253311A1 (en) * 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
JP2007530481A (ja) * 2004-03-24 2007-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング エピナスチン及び１又は２以上の追加のミネラル又は１又は２以上の生薬のコンビネーションを含む皮膚疾患の治療用医薬組成物
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
JP5463019B2 (ja) * 2007-10-12 2014-04-09 第一三共ヘルスケア株式会社 エピナスチン類とエフェドリン類とを含有する気道杯細胞過形成を抑制するための医薬組成物
JP6042084B2 (ja) * 2012-03-19 2016-12-14 ロート製薬株式会社 液状組成物、及びこれを含有する軟カプセル剤
JP5896806B2 (ja) * 2012-03-28 2016-03-30 ロート製薬株式会社 内服組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4231493A1 (de) * 1992-09-21 1994-03-24 Nordmark Arzneimittel Gmbh Verfahren zur Herstellung von Pellets aus einem Ephedrinderivat
JPH083066A (ja) * 1994-06-20 1996-01-09 Takeda Chem Ind Ltd かぜ薬製剤
DE19542281C2 (de) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
JPH1017497A (ja) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
JPH1171281A (ja) * 1997-08-29 1999-03-16 Taisho Pharmaceut Co Ltd 鎮咳効果を有する医薬組成物
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
DE19958460A1 (de) * 1999-12-03 2001-06-07 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Epinastine-Hydrochlorid in der hochschmelzenden Kristallmodifikation
US6613357B2 (en) * 2000-01-13 2003-09-02 Osmotica Corp. Osmotic device containing pseudoephedrine and an H1 antagonist
JP2002087963A (ja) * 2000-09-08 2002-03-27 Nippon Boehringer Ingelheim Co Ltd 直接打錠により製造されたエピナスチン含有錠剤
PE20020324A1 (es) * 2000-10-06 2002-06-18 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas que contienen epinastina y pseudoefedrina
US20020094345A1 (en) * 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
JP2003089638A (ja) * 2001-07-12 2003-03-28 Taisho Pharmaceut Co Ltd 医薬組成物
US20030104017A1 (en) * 2001-10-26 2003-06-05 Boehringer Ingelheim International Gmbh Epinastine formulation for oral administration

Also Published As

Publication number Publication date
UY27920A1 (es) 2004-02-27
MXPA05000071A (es) 2005-04-08
PE20040748A1 (es) 2004-11-25
BR0313175A (pt) 2005-06-14
WO2004014353A1 (en) 2004-02-19
EP1531802A1 (en) 2005-05-25
AU2003250073A1 (en) 2004-02-25
US20050084527A1 (en) 2005-04-21
CA2494065A1 (en) 2004-02-19
JP2006501211A (ja) 2006-01-12

Similar Documents

Publication Publication Date Title
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
UY27553A1 (es) Formulaciones farmacéuticas de 5,7,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2/11),3,5,7,9-pentaeno
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
DE60114635D1 (de) Pharmazeutische formulierungen
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
AR031679A1 (es) Una composicion farmaceutica
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
AR087240A2 (es) Composiciones farmaceuticas que tienen epinastina y pseudoefedrina
ECSP003685A (es) Formulaciones orales de liberacion controlada
ES2175827T3 (es) Formulaciones transmucosas de levosimendano.
AR033596A1 (es) Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
ATE297760T1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
ATE338567T1 (de) Pharmazeutische zubereitungen, wirkstoffe enthaltend, die sich für unerlaubte verabreichung anbieten
ATE400256T1 (de) Pharmazeutische zusammensetzung mit einem kationischen hilfsmittel
BR0111018A (pt) Formulações estáveis lìquidas e sólidas
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
SV2003001422A (es) "1,3-diarilprop-2-en-1-onas,composiciones que las contienen y su utilizacion"
ES2188232T3 (es) Uso de cetirizina para impedir la aparicion del asma.
UY26952A1 (es) Nuevas composiciones farmacéuticas que contienen epinastina y pseudoefedrina

Legal Events

Date Code Title Description
FB Suspension of granting procedure